mhurhangee/patent-ind-claim-en huggingface dataset:
Electronic computer configured to implement at least one critical function, wherein the electronic computer is able to deliver at least one output data item associated with each critical function, and wherein the electronic computer comprises: - at least one control module , wherein each control module is configured to implement a respective critical function and is capable of delivering at least one output data item associated with the critical function; - at least one monitoring module of a control module of another electronic computer , wherein each monitoring module is configured to implement the same respective critical function as the one implemented by the monitored control module ; wherein each control module is configured to receive, from an associated monitoring module of another electronic computer , the result of implementing the corresponding critical function, and to inhibit the delivery of the at least one associated output data item in the event of detection of an inconsistency between the result of its implementation of the respective critical function and that received from the monitoring module of the other electronic computer , wherein each monitoring module is configured to receive, from an associated control module of another electronic computer , the result of implementing the corresponding critical function, and to inhibit the delivery, by the control module , of the at least one associated output data item in the event of detection of an inconsistency between the result of its implementation of the respective critical function and that received from the control module of the other electronic computer . - at least one control module , wherein each control module is configured to implement a respective critical function and is capable of delivering at least one output data item associated with the critical function; - at least one monitoring module of a control module of another electronic computer , wherein each monitoring module is configured to implement the same respective critical function as the one implemented by the monitored control module ;
A pharmaceutical composition for use in treating a neurodegenerative disease comprising: a therapeutic agent that includes a synthetic therapeutic peptide of 5 to 10 amino acids and a transport moiety that is linked to the therapeutic peptide and facilitates uptake of the therapeutic peptide by a cell, the therapeutic peptide inhibiting TDP-43 mediated disassembly of mitochondrial respiratory complex 1 and including an amino acid sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 3.
Rapier weaving machine, comprising an insert rapier head for inserting a weft yarn into a fabric, a receiver rapier head for receiving the weft yarn from the insert rapier head, for holding the weft yarn, and subsequently pulling the weft yarn out of the fabric according to a direction of movement (A), an opening element for opening the receiver rapier head in order to release the weft yarn , and a guiding device positioned on the side of the receiver rapier head , which is opposite the side where the opening element is positioned, for restraining the receiver rapier head when opening this receiver rapier head , and comprising a guiding block for adjusting the direction of movement (A) of the receiver rapier head , characterized in that the guiding device of this rapier weaving machine comprises a guiding wheel positioned rotatably in the guiding device , for restraining the receiver rapier head by means of this guiding wheel when it is opened.
A connector comprising: a male housing ; one or more male blade terminals ; a male blade stabilizer moveable from an extended position relative to the male housing to a retracted position relative to the male housing , the male blade stabilizer including one or more openings through which each of the one or more male blade terminals extend when the male blade stabilizer is in the retracted position, the male blade stabilizer protecting the one or more male blade terminals when the male blade stabilizer is in the extended position, the male blade stabilizer including a retention feature ; and a lever including a lever lock resiliently deflectable relative to the lever, the lever lock selectively engaging with the retention feature of the male blade stabilizer to restrict movement of the male blade stabilizer relative to the male housing and selectively engaging with the male housing to restrict rotation of the lever relative to the male housing ; wherein the lever lock of the lever is resiliently deflected relative to the lever when a female housing of a female connector is engaged with the male housing in a pre-set position. a male housing ; one or more male blade terminals ; a male blade stabilizer moveable from an extended position relative to the male housing to a retracted position relative to the male housing , the male blade stabilizer including one or more openings through which each of the one or more male blade terminals extend when the male blade stabilizer is in the retracted position, the male blade stabilizer protecting the one or more male blade terminals when the male blade stabilizer is in the extended position, the male blade stabilizer including a retention feature ; and a lever including a lever lock resiliently deflectable relative to the lever, the lever lock selectively engaging with the retention feature of the male blade stabilizer to restrict movement of the male blade stabilizer relative to the male housing and selectively engaging with the male housing to restrict rotation of the lever relative to the male housing ; wherein the lever lock of the lever is resiliently deflected relative to the lever when a female housing of a female connector is engaged with the male housing in a pre-set position.
A turbine engine component comprising: an airfoil portion having a leading edge ; a platform ; a leading edge airfoil to platform fillet ; and a cooling tube located within said fillet , said cooling tube having a flared entrance end and a flared exit end ; wherein said leading edge of said airfoil portion includes a leading edge boxcar and an interior portion of said airfoil portion includes a cavity through which cooling air flows; wherein said boxcar has a plurality of cooling film holes ; and wherein said exit end of said cooling tube meets said leading edge boxcar at an end of said leading edge boxcar and said entrance end meets said cavity . an airfoil portion having a leading edge ; a platform ; a leading edge airfoil to platform fillet ; and a cooling tube located within said fillet , said cooling tube having a flared entrance end and a flared exit end ; wherein said leading edge of said airfoil portion includes a leading edge boxcar and an interior portion of said airfoil portion includes a cavity through which cooling air flows; wherein said boxcar has a plurality of cooling film holes ; and wherein said exit end of said cooling tube meets said leading edge boxcar at an end of said leading edge boxcar and said entrance end meets said cavity .
A movement control device comprising: a housing ; an elongate push rod mounted in the housing for reciprocal movement along a longitudinal axis between first and second positions, wherein the push rod extends out of said housing in both the first and second positions, and wherein the second position is a more extended position relative to the first position; a spring comprising a primary axis operable to provide a biasing force on the push rod; and a damping device comprising a primary axis, wherein the damping device is in direct or indirect substantially continuous engagement with the push rod through its reciprocating movement and is configured to provide a damping force on the push rod as it moves from the first position to the second position, wherein the primary axis of the damping device is coaxial with the longitudinal axis of the push rod, charatcerized in that the primary axis of the spring and the primary axis of the damping device are not coaxial. a housing ; an elongate push rod mounted in the housing for reciprocal movement along a longitudinal axis between first and second positions, wherein the push rod extends out of said housing in both the first and second positions, and wherein the second position is a more extended position relative to the first position; a spring comprising a primary axis operable to provide a biasing force on the push rod; and a damping device comprising a primary axis, wherein the damping device is in direct or indirect substantially continuous engagement with the push rod through its reciprocating movement and is configured to provide a damping force on the push rod as it moves from the first position to the second position, wherein the primary axis of the damping device is coaxial with the longitudinal axis of the push rod, charatcerized in that the primary axis of the spring and the primary axis of the damping device are not coaxial.
A method for the identification of microbial and non-microbial infectious pathogens in a body fluid in which infection is suspected, consisting basically of separating the pathogens from a body fluid sample by centrifuging the pathogens into pellets, and subjecting the pathogens to mass spectrometric analysis of their proteins for an identification, further including culturing the pathogens in the body fluid by incubating in order to generate the body fluid sample before the pathogens are centrifuged into pellets and subjected to mass spectrometric identification, wherein the body fluid contains a large number of body fluid particles and is whole blood which requires the method for the identification to include additional steps in order to destroy and remove the body fluid particles.
A wireless power transfer, WPT, pad comprising: a plurality of capacitors (Cs1, Cs2, Cs3); and a winding shaped in a spiral pattern for wireless power transfer, the winding divided into a plurality of winding sections (502, Lp1, Lp2, Lp3, Lp4), wherein the plurality of winding sections are connected in series with one or more capacitors of the plurality of capacitors connected in series between winding sections, and wherein each of the plurality of winding sections is wound in a spiral pattern that expands from a central starting point to an outer ending point, wherein the plurality of spiral patterns are arranged in parallel and characterized in that the plurality of winding sections lie next to each other in a plane such that the spiral patterns are interleaved. a plurality of capacitors (Cs1, Cs2, Cs3); and a winding shaped in a spiral pattern for wireless power transfer, the winding divided into a plurality of winding sections (502, Lp1, Lp2, Lp3, Lp4), wherein the plurality of winding sections are connected in series with one or more capacitors of the plurality of capacitors connected in series between winding sections, and wherein each of the plurality of winding sections is wound in a spiral pattern that expands from a central starting point to an outer ending point, wherein the plurality of spiral patterns are arranged in parallel and characterized in that the plurality of winding sections lie next to each other in a plane such that the spiral patterns are interleaved.
A swabable valve comprising a valve stem that collapses into a valve body , said valve body including a cylindrical reduced diameter section having a circular rim, said swabable valve characterised in that said valve stem comprises a cylindrical reduced diameter portion that seals against said cylindrical reduced diameter section of said valve body , said cylindrical reduced diameter portion including a through-slit that opens when said valve stem collapses into said valve body , said valve stem having a concave curvilinear upper surface that is substantially flush with said circular rim of said cylindrical reduced diameter section of said valve body when said valve stem is not collapsed into said valve body , said concave curvilinear upper surface of said valve stem extending rim-to-rim within said cylindrical reduced diameter section of said valve body .
An on-road running test apparatus for use in a running test for measuring exhaust gas components or fuel consumption of a vehicle (V) comprising: a running data acquisition part for sequentially acquiring actual running data of the vehicle (V) under execution of the running test on a road; the test apparatus characterized in that it further comprises a tendency data output part for sequentially producing and outputting tendency data indicating a tendency as to whether or not the running test for measuring exhaust gas components or fuel consumption is valid, based on the actual running data during the running test. a running data acquisition part for sequentially acquiring actual running data of the vehicle (V) under execution of the running test on a road; the test apparatus characterized in that it further comprises a tendency data output part for sequentially producing and outputting tendency data indicating a tendency as to whether or not the running test for measuring exhaust gas components or fuel consumption is valid, based on the actual running data during the running test.
An anionic drug-containing medical device comprising: an anionic drug; and a hydrogel comprising a copolymer which contains, as constituent, i) a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and ii) a hydrophilic monomer capable of copolymerizing with the condensation product or the salt of the condensation product and iii) a cross-linking monomer capable of copolymerizing with the condensation product or the salt of the condensation product. an anionic drug; and a hydrogel comprising a copolymer which contains, as constituent, i) a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and ii) a hydrophilic monomer capable of copolymerizing with the condensation product or the salt of the condensation product and iii) a cross-linking monomer capable of copolymerizing with the condensation product or the salt of the condensation product. i) a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and ii) a hydrophilic monomer capable of copolymerizing with the condensation product or the salt of the condensation product and iii) a cross-linking monomer capable of copolymerizing with the condensation product or the salt of the condensation product.
A gas analyzing apparatus comprising: a tube-like member that includes a light path through which measurement light can be emitted to a predetermined measurement region of sample gas (S) flowing in a pipe and/or through which the measurement light from the measurement region can be received, the tube-like member having a flange configured to be fixed to the pipe side wall so that the tube-like member is arranged in an opening of the pipe side wall so as to define a gap between a tube-like inner wall surface of the opening and an outer circumferential surface of the tube-like member; an optical system member configured to emit the measurement light to the sample gas (S) in the measurement region and/or to receive the measurement light from the measurement region; a purge gas feed portion configured to supply purge gas (Pa) to a region positioned on a light path of the measurement light between the optical system member and the measurement region; and at least one blocking plate disposed around a periphery of the tube-like member at a position close to the inner wall surface of the pipe side wall so as to suppress the sample gas (S) from flowing from the pipe into the gap . a tube-like member that includes a light path through which measurement light can be emitted to a predetermined measurement region of sample gas (S) flowing in a pipe and/or through which the measurement light from the measurement region can be received, the tube-like member having a flange configured to be fixed to the pipe side wall so that the tube-like member is arranged in an opening of the pipe side wall so as to define a gap between a tube-like inner wall surface of the opening and an outer circumferential surface of the tube-like member; an optical system member configured to emit the measurement light to the sample gas (S) in the measurement region and/or to receive the measurement light from the measurement region; a purge gas feed portion configured to supply purge gas (Pa) to a region positioned on a light path of the measurement light between the optical system member and the measurement region; and at least one blocking plate disposed around a periphery of the tube-like member at a position close to the inner wall surface of the pipe side wall so as to suppress the sample gas (S) from flowing from the pipe into the gap .
An anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2 and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 1, 2 and 3, respectively, and CDR1, CDR2 and CDR3 light chain sequences as set forth in SEQ ID NOs: 4, 5 and 6, respectively, for use in a method of treating a human patient with a protein-losing enteropathy wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered at a dose of: (i) 600 mg to a patient weighing 10 kg to <20 kg twice per week during weeks 1 and 2 of the administration cycle and once during week 3, followed by 300 mg or 600 mg once per week during weeks 4 and 5 and every two weeks thereafter; (ii) 600 mg to a patient weighing 20 kg to <30 kg twice per week during weeks 1 and 2 of the administration cycle, followed by 600 mg once per week during weeks 3, 4 and 5 and every two weeks thereafter; (iii) 900 mg to a patient weighing 30 kg to <40 kg twice per week during weeks 1 and 2 of the administration cycle, followed by 900 mg once per week during weeks 3, 4 and 5 and every two weeks thereafter; or (iv) 1200 mg to a patient weighing ≥40 kg twice per week during weeks 1 and 2 of the administration cycle, followed by 1200 mg once per week during weeks 3, 4 and 5 and every two weeks thereafter. (i) 600 mg to a patient weighing 10 kg to <20 kg twice per week during weeks 1 and 2 of the administration cycle and once during week 3, followed by 300 mg or 600 mg once per week during weeks 4 and 5 and every two weeks thereafter; (ii) 600 mg to a patient weighing 20 kg to <30 kg twice per week during weeks 1 and 2 of the administration cycle, followed by 600 mg once per week during weeks 3, 4 and 5 and every two weeks thereafter; (iii) 900 mg to a patient weighing 30 kg to <40 kg twice per week during weeks 1 and 2 of the administration cycle, followed by 900 mg once per week during weeks 3, 4 and 5 and every two weeks thereafter; or (iv) 1200 mg to a patient weighing ≥40 kg twice per week during weeks 1 and 2 of the administration cycle, followed by 1200 mg once per week during weeks 3, 4 and 5 and every two weeks thereafter.
Rolled wire rod comprising, by mass%, C: 0.20% to less than 0.40%, Mn: 0.10% to less than 0.40%, S: less than 0.020%, P: less than 0.020%, Cr: 0.70% to 1.60%, Al: 0.005% to 0.060%, Ti: 0.010% to 0.080%, B: 0.0003% to 0.0040%, and N: 0.0020% to 0.0080% and optionally at least one type of Si: 0% to less than 0.40%, Nb: 0% to 0.050%, Cu: 0.50% or less, Ni: 0.30% or less, Mo: 0.05 % or less, V: 0.05 % or less; Zr: 0.05% or less, Ca: 0.005% or less and Mg: 0.005% or less and having a balance of Fe and impurities, wherein if the contents of Ti, N, and S in mass% are respectively [Ti], [N], and [S], if [S]≤0.0010, [Ti] is (4.5×[S]+3.4×[N]) or more and (0.008+3.4×[N]) or less, while if [S]≥0.0010, [Ti] is (4.5×[S]+3.4×[N]) or more and (8.0×[S]+3.4×[N]) or less, the internal structure is a mixed structure of ferrite and pearlite of an area rate of 95% or more with an area rate of a ferrite fraction of 40% or more, and a mean area of sulfides present in a range from a surface to a D/8 position is less than 6 μm 2 in the case of a diameter of D in mm in a cross-section at a plane including the axial direction, and a mean aspect ratio of the sulfides is 5 or less, wherein the microstructure, the mean area of sulfides and mean aspect ratio of the sulfides are measured as described in the description. C: 0.20% to less than 0.40%, Mn: 0.10% to less than 0.40%, S: less than 0.020%, P: less than 0.020%, Cr: 0.70% to 1.60%, Al: 0.005% to 0.060%, Ti: 0.010% to 0.080%, B: 0.0003% to 0.0040%, and N: 0.0020% to 0.0080% and optionally at least one type of Si: 0% to less than 0.40%, Nb: 0% to 0.050%, Cu: 0.50% or less, Ni: 0.30% or less, Mo: 0.05 % or less, V: 0.05 % or less; Zr: 0.05% or less, Ca: 0.005% or less and Mg: 0.005% or less and having a balance of Fe and impurities, wherein if the contents of Ti, N, and S in mass% are respectively [Ti], [N], and [S], if [S]≤0.0010, [Ti] is (4.5×[S]+3.4×[N]) or more and (0.008+3.4×[N]) or less, while if [S]≥0.0010, [Ti] is (4.5×[S]+3.4×[N]) or more and (8.0×[S]+3.4×[N]) or less, the internal structure is a mixed structure of ferrite and pearlite of an area rate of 95% or more with an area rate of a ferrite fraction of 40% or more, and a mean area of sulfides present in a range from a surface to a D/8 position is less than 6 μm 2 in the case of a diameter of D in mm in a cross-section at a plane including the axial direction, and a mean aspect ratio of the sulfides is 5 or less, wherein the microstructure, the mean area of sulfides and mean aspect ratio of the sulfides are measured as described in the description.
An ophthalmic lens comprising a transparent polymer matrix and core shell nanoparticles which are dispersed in the transparent polymer matrix, wherein: • The core of core shell nanoparticles results from polymerization of a composition comprising nanoparticle core precursors and at least one photochromic compound, • The shell of core shell nanoparticles comprises a mineral compound, wherein the amount of photochromic compound in the core-shell nanoparticles is from 0.0001 to 90 wt%, in particular from 0.01 to 50% wt%, more particularly from 0.1 to 10 wt% based on the total weight of the core-shell nanoparticles, and wherein the refractive index of the core-shell nanoparticles ranges from 1.47 to 1.74. • The core of core shell nanoparticles results from polymerization of a composition comprising nanoparticle core precursors and at least one photochromic compound, • The shell of core shell nanoparticles comprises a mineral compound,